Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 1.00 |
| ▸ | POLB | P06746 | 3/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.72 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.72 |
| ▸ | HTT | P42858 | 2/20 | 0.69 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | RAB9A | P51151 | 3/20 | 0.55 |
| ▸ | NPC1 | O15118 | 3/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20346316 | 0.98 | SMN1; SMN2 (0.97) | SMN1; SMN2POLBALDH1A1HSD17B10HTT | |
| SCHEMBL24815673 | 0.80 | SMN1; SMN2 (0.67) | SMN1; SMN2POLBALDH1A1HSD17B10HTT | |
| SCHEMBL29986910 | 0.80 | SMN1; SMN2 (0.67) | SMN1; SMN2POLBALDH1A1HSD17B10HTT | |
| SCHEMBL12385780 | 0.80 | SMN1; SMN2 (0.66) | SMN1; SMN2POLBALDH1A1HSD17B10GAA | |
| SCHEMBL19277488 | 0.79 | POLB (0.65) | SMN1; SMN2POLBALDH1A1HSD17B10HTT | |
| SCHEMBL12384423 | 0.77 | SMN1; SMN2 (0.61) | SMN1; SMN2POLBALDH1A1HSD17B10HTT | |
| SCHEMBL19277458 | 0.76 | POLB (0.61) | SMN1; SMN2POLBALDH1A1HSD17B10HTT | |
| SCHEMBL6032510 | 0.76 | SMN1; SMN2 (0.60) | SMN1; SMN2POLBALDH1A1HSD17B10HTT | |
| SCHEMBL1493731 | 0.75 | POLB (0.60) | SMN1; SMN2POLBALDH1A1HTTRAB9A | |
| SCHEMBL1463428 | 0.74 | SMN1; SMN2 (0.58) | SMN1; SMN2POLBALDH1A1HSD17B10HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110201593-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2011-08-18 | — | — | US | disclosed |
| WO-2011086053-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2011-07-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110201593-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | CCNY, CCNA1, CCNA2 | SMN1; SMN2 4086/4885POLB 660/4885ALDH1A1 1168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.